Phase 1 study of NY-ESO-1 vaccine + ipilimumab (IPI) in patients with unresectable or metastatic melanoma.

Craig L. Slingluff,Hassane M. Zarour,Michael A. Postow,Philip Friedlander,Craig Devoe,Kelly Smith,Donna H. Deacon,Mary J. Macri,Aileen Ryan,Ralph Venhaus,Jedd D. Wolchok

Phase 1 study of NY-ESO-1 vaccine + ipilimumab (IPI) in patients with unresectable or metastatic melanoma.

2018

Craig L. Slingluff
Hassane M. Zarour
Michael A. Postow
Philip Friedlander
Craig Devoe
Kelly Smith
Donna H. Deacon
Mary J. Macri
Aileen Ryan
Ralph Venhaus
Jedd D. Wolchok

e15175Background: IPI is an approved immunotherapy for advanced melanoma; it has enhanced spontaneous immunity to NY-ESO-1, a cancer-testis antigen expressed by some melanomas. NY-ESO-1 vaccines ha...

Keywords:

Melanoma
Ipilimumab
Pathology
NY-ESO-1
Cancer research
Medicine
Immunotherapy
metastatic melanoma
Oncology
advanced melanoma
in patient
Internal medicine
Antigen
Immunity

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations